IdentificationGeneric Name({3-[1-(4-Hydroxy-2-oxo-2H-chromen-3-yl)-propyl]-phenylcarbamoyl}-methyl)-carbamic acid tert-butyl esterDrugBank Accession NumberDB08664BackgroundNot AvailableTypeSmall MoleculeGroupsExperimentalStructure


3DDownload MOLSDF3D-SDFPDBSMILESInChI


 Similar StructuresStructure for ({3-[1-(4-Hydroxy-2-oxo-2H-chromen-3-yl)-propyl]-phenylcarbamoyl}-methyl)-carbamic acid tert-butyl ester (DB08664)× CloseWeightAverage: 452.4996 Monoisotopic: 452.194736638 Chemical FormulaC25H28N2O6Synonymstert-butyl N-[({3-[(1S)-1-(4-hydroxy-2-oxo-2H-chromen-3-yl)propyl]phenyl}carbamoyl)methyl]carbamatePharmacologyIndicationNot AvailableReduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, & validate predictive machine-learning models with structured datasets.See howContraindications & Blackbox WarningsAvoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Learn more  Avoid life-threatening adverse drug events & improve clinical decision support.Learn morePharmacodynamicsNot AvailableMechanism of actionTargetActionsOrganismUGag-Pol polyproteinNot AvailableHIV-2AbsorptionNot AvailableVolume of distributionNot AvailableProtein bindingNot AvailableMetabolismNot AvailableRoute of eliminationNot AvailableHalf-lifeNot AvailableClearanceNot AvailableAdverse EffectsImprove decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Learn more  Improve decision support & research outcomes with our structured adverse effects data.Learn moreToxicityNot AvailablePathwaysNot AvailablePharmacogenomic Effects/ADRs 


Not AvailableInteractionsDrug Interactions 


This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. Not AvailableFood InteractionsNot AvailableCategoriesDrug CategoriesNot AvailableChemical TaxonomyProvided by ClassyfireDescriptionThis compound belongs to the class of organic compounds known as 4-hydroxycoumarins. These are coumarins that contain one or more hydroxyl groups attached to C4-position the coumarin skeleton.KingdomOrganic compoundsSuper ClassPhenylpropanoids and polyketidesClassCoumarins and derivativesSub ClassHydroxycoumarinsDirect Parent4-hydroxycoumarinsAlternative ParentsAlpha amino acid amides / 1-benzopyrans / Phenylpropanes / Anilides / N-arylamides / Pyranones and derivatives / Vinylogous acids / Carbamate esters / Heteroaromatic compounds / Secondary carboxylic acid amides / Organic carbonic acids and derivatives / Lactones / Oxacyclic compounds / Hydrocarbon derivatives / Organic oxides / Organopnictogen compounds / Carbonyl compounds


 show 7 moreSubstituents1-benzopyran / 4-hydroxycoumarin / Alpha-amino acid amide / Alpha-amino acid or derivatives / Anilide / Aromatic heteropolycyclic compound / Benzenoid / Benzopyran / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Heteroaromatic compound / Hydrocarbon derivative / Lactone / Monocyclic benzene moiety / N-arylamide / N-substituted-alpha-amino acid / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organoheterocyclic compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Oxacycle / Phenylpropane / Pyran / Pyranone / Secondary carboxylic acid amide / Vinylogous acid


 show 22 moreMolecular FrameworkAromatic heteropolycyclic compoundsExternal DescriptorsNot AvailableAffected organismsNot AvailableChemical IdentifiersUNIINot AvailableCAS numberNot AvailableInChI KeyQUQQVMVIWCUYFV-KRWDZBQOSA-NInChIInChI=1S/C25H28N2O6/c1-5-17(21-22(29)18-11-6-7-12-19(18)32-23(21)30)15-9-8-10-16(13-15)27-20(28)14-26-24(31)33-25(2,3)4/h6-13,17,29H,5,14H2,1-4H3,(H,26,31)(H,27,28)/t17-/m0/s1IUPAC Nametert-butyl N-[({3-[(1S)-1-(4-hydroxy-2-oxo-2H-chromen-3-yl)propyl]phenyl}carbamoyl)methyl]carbamateSMILESCC[C@@H](C1=CC(NC(=O)CNC(=O)OC(C)(C)C)=CC=C1)C1=C(O)C2=CC=CC=C2OC1=OReferencesGeneral ReferencesNot AvailableExternal LinksPubChem Compound54689025PubChem Substance99445135ChemSpider25058338BindingDB1924ZINCZINC000100036952PDBe LigandU04PDB Entries4upjClinical TrialsClinical Trials 


PhaseStatusPurposeConditionsCountPharmacoeconomicsManufacturersNot AvailablePackagersNot AvailableDosage FormsNot AvailablePricesNot AvailablePatentsNot AvailablePropertiesStateSolidExperimental PropertiesNot AvailablePredicted PropertiesPropertyValueSourceWater Solubility0.00464 mg/mLALOGPSlogP3.59ALOGPSlogP3.54ChemaxonlogS-5ALOGPSpKa (Strongest Acidic)5.49ChemaxonpKa (Strongest Basic)-6.7ChemaxonPhysiological Charge-1ChemaxonHydrogen Acceptor Count4ChemaxonHydrogen Donor Count3ChemaxonPolar Surface Area113.96 Å2ChemaxonRotatable Bond Count8ChemaxonRefractivity124.74 m3·mol-1ChemaxonPolarizability48.45 Å3ChemaxonNumber of Rings3ChemaxonBioavailability1ChemaxonRule of FiveYesChemaxonGhose FilterYesChemaxonVeber's RuleNoChemaxonMDDR-like RuleYesChemaxonPredicted ADMET FeaturesPropertyValueProbabilityHuman Intestinal Absorption+0.7874Blood Brain Barrier-0.9063Caco-2 permeable-0.6917P-glycoprotein substrateSubstrate0.8705P-glycoprotein inhibitor INon-inhibitor0.5565P-glycoprotein inhibitor IINon-inhibitor0.943Renal organic cation transporterNon-inhibitor0.9587CYP450 2C9 substrateNon-substrate0.7532CYP450 2D6 substrateNon-substrate0.8156CYP450 3A4 substrateSubstrate0.6262CYP450 1A2 substrateNon-inhibitor0.6562CYP450 2C9 inhibitorNon-inhibitor0.7535CYP450 2D6 inhibitorNon-inhibitor0.8532CYP450 2C19 inhibitorNon-inhibitor0.5952CYP450 3A4 inhibitorNon-inhibitor0.8965CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6574Ames testNon AMES toxic0.6968CarcinogenicityNon-carcinogens0.7943BiodegradationNot ready biodegradable1.0Rat acute toxicity2.7411 LD50, mol/kg Not applicablehERG inhibition (predictor I)Weak inhibitor0.975hERG inhibition (predictor II)Non-inhibitor0.8691  ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397) SpectraMass Spec (NIST)Not AvailableSpectraSpectrumSpectrum TypeSplash KeyPredicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot AvailableTargetsBuild, predict & validate machine-learning modelsUse our structured and evidence-based datasets to unlock newinsights and accelerate drug research.Learn more  Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.Learn more


 Details1. Gag-Pol polyproteinKindProteinOrganismHIV-2Pharmacological actionUnknownGeneral FunctionZinc ion bindingSpecific FunctionGag-Pol polyprotein: Mediates, with Gag polyrotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spher...Gene Namegag-polUniprot IDP04584Uniprot NameGag-Pol polyproteinMolecular Weight164644.035 DaReferencesBerman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article] ×Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice. Learn more   Drug created at September 15, 2010 21:33 / Updated at June 12, 2020 16:52 